Top High Growth Tech Stocks to Watch in September 2024

In This Article:

As global markets rebound from recent sell-offs, technology stocks have led the charge, significantly outpacing their value counterparts. With the S&P 500 Index recovering from its steepest decline since March 2023 and core inflation slightly higher than expected, investors are keenly watching high-growth tech stocks that can capitalize on these dynamic market conditions. In this context, a good stock to watch in the high-growth tech sector is one that demonstrates strong performance metrics and has a positive outlook bolstered by current market sentiment.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.41%

27.42%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Sarepta Therapeutics

23.58%

44.12%

★★★★★★

Medley

24.98%

30.36%

★★★★★★

Scandion Oncology

40.71%

75.34%

★★★★★★

G1 Therapeutics

27.57%

57.75%

★★★★★★

KebNi

34.75%

86.11%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Adocia

59.08%

63.00%

★★★★★★

Travere Therapeutics

26.68%

68.80%

★★★★★★

Click here to see the full list of 1275 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Trade Desk

Simply Wall St Growth Rating: ★★★★★☆

Overview: The Trade Desk, Inc. is a technology company that provides a global self-service software platform for ad buyers, with a market cap of approximately $51.80 billion.

Operations: Trade Desk generates revenue primarily from its software and programming segment, which brought in approximately $2.17 billion. The company operates both in the United States and internationally, focusing on providing a self-service platform for ad buyers.

Trade Desk has demonstrated substantial growth, with earnings rising by 95.9% over the past year and revenue forecasted to grow at 17.4% annually, outpacing the US market's 8.7%. The company repurchased 11.65 million shares for $773.08 million under its recent buyback program, indicating strong confidence in its future prospects. Their innovative solutions like Unified ID 2.0 and OpenPass are enhancing advertiser capabilities and publisher relationships, addressing key industry challenges around privacy and user engagement.

NasdaqGM:TTD Revenue and Expenses Breakdown as at Sep 2024
NasdaqGM:TTD Revenue and Expenses Breakdown as at Sep 2024

Vertex Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for treating cystic fibrosis (CF) with a market cap of $126.32 billion.